Found 231 Enz. Inhib. hit(s) with all data for entry = 6704 TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 0.380nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 0.430nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 0.5nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 0.540nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 0.570nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 0.630nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 0.640nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 0.670nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 0.730nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 0.740nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 0.740nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 0.780nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 0.780nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 0.810nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 0.820nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 0.880nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 0.880nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 0.900nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 0.920nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 0.970nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 1nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 1.10nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 1.10nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 1.20nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 1.20nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 1.30nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 1.30nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 1.30nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 1.30nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 1.30nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 1.30nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 1.30nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 1.40nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 1.40nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 1.5nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 1.60nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 1.70nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 1.80nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 1.80nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 1.90nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 1.90nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 1.90nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 1.90nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 1.90nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 2nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 2nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 2nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 2nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 2nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
TargetLymphokine-activated killer T-cell-originated protein kinase(Homo sapiens (Human))
Oncotherapy Science
US Patent
Oncotherapy Science
US Patent
Affinity DataIC50: 2.20nMpH: 7.4 T: 2°CAssay Description:PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a s...More data for this Ligand-Target Pair
